There is provided a device and method for separation of blood, including sedimentation of plasma using PVA. The device comprises an inner container enclosed in an outer container, wherein upon alignment of respective openings, allows sample to exit from the inner container into a reaction structure. The reaction structure comprises one or more layers, each with one or more portions each containing concentrations of one or more chemicals.

Non-naturally occurring peptides are provided that act as a Src SH2 domain antagonist of cardiotonic steroids. Pharmaceutical compositions comprising the peptides are also provided along with vectors encoding the peptides. Methods of treating a Src-associated disease and reducing Src activity in a cell are further provided and include administering or contacting a cell with an effective amount of the peptide.

There is provided a device and method for separation of blood, including sedimentation of plasma using PVA. The device comprises an inner container enclosed in an outer container, wherein upon alignment of respective openings, allows sample to exit from the inner container into a reaction structure. The reaction structure comprises one or more layers, each with one or more portions each containing concentrations of one or more chemicals.

There is provided a device and method for separation of blood, including sedimentation of plasma using PVA. The device comprises an inner container enclosed in an outer container, wherein upon alignment of respective openings, allows sample to exit from the inner container into a reaction structure. The reaction structure comprises one or more layers, each with one or more portions each containing concentrations of one or more chemicals.

Provided herein are methods for inhibiting contraction and/or promoting relaxation of airway smooth muscle cells (e.g., human airway smooth muscle cells), comprising contacting the cells with a G.sub.12 or RhoA inhibitor. Also provided herein are methods for inhibiting and/or treating bronchoconstriction or promoting bronchodilation in a subject, for example, a subject with airway hyperresponsiveness and/or a disease associated with bronchoconstriction, such as asthma, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis or cystic fibrosis, using a G.sub.12 or RhoA inhibitor, as well as pharmaceutical compositions comprising a G.sub.12 or RhoA inhibitor.

Provided herein are methods for inhibiting contraction and/or promoting relaxation of airway smooth muscle cells (e.g., human airway smooth muscle cells), comprising contacting the cells with a G.sub.12 or RhoA inhibitor. Also provided herein are methods for inhibiting and/or treating bronchoconstriction or promoting bronchodilation in a subject, for example, a subject with airway hyperresponsiveness and/or a disease associated with bronchoconstriction, such as asthma, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis or cystic fibrosis, using a G.sub.12 or RhoA inhibitor, as well as pharmaceutical compositions comprising a G.sub.12 or RhoA inhibitor.

Provided in the present disclosure is a method for sequencing a double-stranded target polynucleotide. The method can keep ATP at a relatively constant concentration during sequencing, so that the sequencing rate can be better kept stable and unchanged. Further provided in the present disclosure is a kit for sequencing a double-stranded target polynucleotide, the kit including a transmembrane pore in the membrane, a helicase, an ATP-generating enzyme and an ATP-generating substrate.

Provided in the present disclosure is a method for sequencing a double-stranded target polynucleotide. The method can keep ATP at a relatively constant concentration during sequencing, so that the sequencing rate can be better kept stable and unchanged. Further provided in the present disclosure is a kit for sequencing a double-stranded target polynucleotide, the kit including a transmembrane pore in the membrane, a helicase, an ATP-generating enzyme and an ATP-generating substrate.

There is provided a device and method for separation of blood, including sedimentation of plasma using PVA. The device comprises an inner container enclosed in an outer container, wherein upon alignment of respective openings, allows sample to exit from the inner container into a reaction structure. The reaction structure comprises one or more layers, each with one or more portions each containing concentrations of one or more chemicals.

There is provided a device and method for separation of blood, including sedimentation of plasma using PVA. The device comprises an inner container enclosed in an outer container, wherein upon alignment of respective openings, allows sample to exit from the inner container into a reaction structure. The reaction structure comprises one or more layers, each with one or more portions each containing concentrations of one or more chemicals.